Navigation Links
Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Date:6/11/2008

Interim Results Show Promise for Improving the Treatment of Blockages in

the Femoropopliteal Artery

VANCOUVER, June 11 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that its corporate partner, Cook Medical, has reported positive interim results from the registry arm of a clinical study measuring the effectiveness of its Zilver PTX drug-eluting peripheral stent in treating peripheral arterial disease (PAD). The results, which were reported by the trial investigators last week at the 2008 SVS Vascular Annual Meeting, revealed clinical improvement, excellent durability and fracture resistance, and high rates of event-free survival (EFS) and freedom from target lesion revascularization (TLR). In addition, the Zilver stent exhibited no safety concerns and results were better than expected for TASC class C and D lesions, occlusions, in-stent restenosis and lesions greater than seven centimetres (2.75 inches).

"Building on the success of our paclitaxel-eluting coronary stents, we are extremely pleased that Cook has met with early success in leveraging our technology with this first round of positive trial data for the Zilver PTX paclitaxel-eluting peripheral stent," said Dr. William Hunter, President and CEO of Angiotech. "We are hopeful that Cook will encounter similarly positive results throughout the duration of the Zilver PTX trial and we are excited about the potential benefits the Zilver PTX stent may provide patients suffering from PAD."

Interim data was compiled at six and 12 months using 435 patients and 200 patients, respectively. The corresponding EFS rates were 94 percent and
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... The next implants made from the ... mark (European) approval. The CE mark is necessary for ... and the European Union. Following the Class IIb approval ... implants supplied by the Turkey-based company Osimplant for the ... Cervical Expandable Bladed HA PEEK Cage line of spinal ...
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... CALGARY , March 4, 2015 /CNW/ ... that it has completed a collaborative research ... quantitative analytics.  Using Fast Collective Evolution Technology ... dataset including all measurements obtained from each ... Company,s Phase 2 clinical trials ASSERT, SUSTAIN ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... Dendreon Corporation,(Nasdaq: DNDN ) will release its fourth quarter financial ... call at,8:00 a.m. PT; 11:00 a.m. ET to review fiscal year ... may be,obtained as follows:, Time: ... March 13, 2008 Dial-in: 1-877-548-7901 ...
... Calif., March 6 ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), ... ISTA reported net revenue of $58.9 million for the year,ended ... results of,$33.0 million. Net revenue in the fourth quarter of ... was a year of success and challenges. On the commercial ...
... LLC, a leading global laboratory,supply company, will hold a conference call on Wednesday, March 12th ... John M. Ballbach, Chairman, President and CEO ... Executive Vice-President & Chief ... Wednesday, March 12, 2008 ...
Cached Biology Technology:-Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET- 2ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8VWR Funding, Inc. to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call 2
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... ... A new survey conducted by WCS scientists, supported by the ... Asiatic black bears, gray wolves, markhor goats, and leopard cats are ... field team used camera-trap surveys, transect surveys, and DNA identification of ...
... , New Rochelle, NY, June 27, 2011Sophisticated genetic tools ... gene expression levels in bone marrow will drive the ... range of diseases. Examples of these cutting-edge methods are ... the latest issue of Human Gene Therapy , ...
... of researchers from the National Institute of Standards ... University of Maryland has made nano-sized sensors that ... cleaners, pesticides and other productsthat offer several advantages ... operation and the ability to detect one or ...
Cached Biology News:Wildlife surviving conflict in Afghanistan 2Wildlife surviving conflict in Afghanistan 3The promise of stem cell-based gene therapy 2Nanowire-based sensors offer improved detection of volatile organic compounds 2
... Thermo Forma's stainless ... a patented adjustable mechanism ... 6 different shaking angles, ... rack placement.This universal rack ...
... 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat inactivation ... Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM KCl, ... BSA, 50% glycerol. Shipping and Storage: Shipped on ... unit is defined as the amount of enzyme ...
... shaker flask clips, purpose-designed to firmly retain ... clips are equipped with a top retainer ... a bottom retainer spring, and silicon tubing ... glassware. Clips include the required mounting ...
ANTI DIPHTH TOX A SU...
Biology Products: